Nurix Therapeutics, Inc. cotiza a 22.16 USD y tiene una capitalización bursátil de $2.3B. En los últimos 12 meses ha facturado $37M con un margen de flujo de caja libre del -313.7%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is…
| Periodo | 2026-10 | 2026-07 | 2026-04 | 2026-01 |
|---|---|---|---|---|
| Real | $4.73 | $-0.81 | $-0.79 | $-0.82 |
| Estimado | $5.11 | $-0.72 | $-0.76 | $-0.92 |
| Sorpresa | -7.4% | -12.5% | -3.9% | +10.9% |
| Métrica | NRIX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -340.2% | -38.6% | -301.5% |
| Net Margin | -314.9% | -33.6% | -281.3% |
| FCF Margin | -313.7% | -13.9% | -299.9% |
| ROE | -49.1% | -40.4% | -8.7% |
| ROA | -38.4% | -32.0% | -6.4% |
| Current Ratio | 7.02 | 2.84 | +4.18 |
| Debt / Equity | — | 0.28 | — |